Why the study?
Atrial fibrillation in hypertrophic cardiomyopathy leads to functional decline, increased thromboembolic disease, and heightened mortality, requiring a review of its development, clinical impact, and management.
This review highlights the pathophysiology, clinical impact, and management strategies for atrial fibrillation in patients with hypertrophic cardiomyopathy.
Synthesizes evidence on AF in HCM; leaves open need for dedicated RCTs to guide therapy.
Hypertrophic cardiomyopathy (HCM) is an inherited cardiological condition that exhibits various clinical symptoms. The leading cause of atrial fibrillation (AF) in patients with HCM is advanced diastolic dysfunction and left atrial dilatation and remodeling. In addition to the gradual symptomatic and functional decline caused by AF, there is an increased risk of thromboembolic disease and mortality, especially if there is a rapid ventricular rate or obstruction of the left ventricular outflow tract. The mainstay of management of AF in HCM is a combination of non-pharmacological lifestyle and risk factor modification, long-term anticoagulation, and rhythm control with anti-arrhythmic medications, septal ablation, and radiofrequency catheter ablation. This article has examined the development of AF in HCM, its clinical symptomatology, and its impact, highlighting its management and the mortality associated with AF in HCM.
No takes yet. Share an insight, caveat, or question.
Palyam et al. (2022) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: